One step forward in health promotion.

Journal of medicine and life 20120915

Chelation of aluminum by combining deferasirox and deferiprone in rats.

Toxicology and industrial health 20120901

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Haematologica 20120901

Deferasirox treatment for myelodysplastic syndromes: 'real-life' efficacy and safety in a single-institution patient population.

Annals of hematology 20120901

Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.

Annals of hematology 20120901

Acute effects of blood transfusion on pituitary gonadal axis and sperm parameters in adolescents and young men with thalassemia major: a pilot study.

Fertility and sterility 20120901

Effects of oral iron chelator deferasirox on human malignant lymphoma cells.

The Korean journal of hematology 20120901

Formation of ultrafine deferasirox particles via rapid expansion of supercritical solution (RESS process) using Taguchi approach.

International journal of pharmaceutics 20120820

Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.

Free radical biology & medicine 20120815

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Blood 20120802

Iron out for nontransfused thalassemia.

Blood 20120802

Risk factors for mortality in patients with mucormycosis.

Medical mycology 20120801

Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.

Leukemia research 20120801

Selective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS.

Leukemia research 20120801

Deferasirox for porphyria cutanea tarda: a pilot study.

Archives of dermatology 20120801

Deferiprone is superior to deferasirox and desferrioxamine in cardiac iron overload.

Indian pediatrics 20120801

Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120610

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

Haematologica 20120601

First report of drug-induced esophagitis by deferasirox.

International journal of hematology 20120601

Iron mobilization using chelation and phlebotomy.

Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 20120601

A case of GH deficiency and beta-thalassemia.

Minerva endocrinologica 20120601

Unrelated hematopoietic stem cell transplantation in a patient with congenital dyserythropoietic anemia and iron overload.

Pediatric transplantation 20120501

Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).

Annals of hematology 20120501

Safety of deferasirox in sickle cell disease patients with co-existing liver impairment.

British journal of haematology 20120501

Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.

European journal of haematology 20120501

Metals and the liver.

Current opinion in gastroenterology 20120501

Deferasirox therapy in children with Fanconi aplastic anemia.

Journal of pediatric hematology/oncology 20120501

Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

Blood 20120426

Hydrophilic interaction liquid chromatography/positive ion electrospray mass spectrometry for the quantification of deferasirox, an oral iron chelator, in human plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120415

A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120415

Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.

Journal of pharmaceutical and biomedical analysis 20120407

Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.

Journal of clinical pharmacy and therapeutics 20120401

Oxidative stress and antioxidant capacity in sickle cell anaemia patients receiving different treatments and medications for different periods of time.

Annals of hematology 20120401

Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.

Indian pediatrics 20120401

Non-systemic drugs: a critical review.

Current pharmaceutical design 20120401

Iron overload during follow-up after tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma.

Journal of Korean medical science 20120401

Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.

Blood 20120322

Long-term efficacy of deferasirox in preventing cardiovascular complications in the iron-overloaded gerbil.

Journal of cardiovascular pharmacology and therapeutics 20120301

Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors.

Pediatric blood & cancer 20120301

Circulating CD133(+)VEGFR2 (+) and CD34 (+)VEGFR2 (+) cells and arterial function in patients with beta-thalassaemia major.

Annals of hematology 20120301

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

The Journal of antimicrobial chemotherapy 20120301

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.

European journal of haematology 20120301

Deferasirox in mucormycosis: hopefully, not defeated.

The Journal of antimicrobial chemotherapy 20120301

Deferasirox as adjunctive therapy for mucormycosis.

The Journal of antimicrobial chemotherapy 20120301

4-[3,5-Bis(2-hy-droxy-phen-yl)-1H-1,2,4-triazol-1-yl]benzoic acid dimethyl-formamide monosolvate.

Acta crystallographica. Section E, Structure reports online 20120301

Deferasirox for managing iron overload in people with thalassaemia.

The Cochrane database of systematic reviews 20120215

Deferasirox increases BU blood concentrations.

Bone marrow transplantation 20120201

The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis.

Infection 20120201

Removal of cadmium by combining deferasirox and desferrioxamine chelators in rats.

Toxicology and industrial health 20120201

Combination therapy for mucormycosis: why, what, and how?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120201

Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics.

Nagoya journal of medical science 20120201

A case of selective mutism in an 8-year-old girl with thalassaemia major after bone marrow transplantation.

Pharmacopsychiatry 20120101

Invasive mold infections: virulence and pathogenesis of mucorales.

International journal of microbiology 20120101

Deferasirox: pharmacokinetics and clinical experience.

Expert opinion on drug metabolism & toxicology 20120101

Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report.

Journal of pediatric hematology/oncology 20120101

Iron - A Key Nexus in the Virulence of Aspergillus fumigatus.

Frontiers in microbiology 20120101

Altered mental status and low anion gap in a patient with sickle cell anemia: a case report.

Journal of medical case reports 20120101

[Iron overload and iron chelation therapy].

[Rinsho ketsueki] The Japanese journal of clinical hematology 20120101

[MDS].

[Rinsho ketsueki] The Japanese journal of clinical hematology 20120101

[Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes].

[Rinsho ketsueki] The Japanese journal of clinical hematology 20120101

Molecular diagnostic and pathogenesis of hereditary hemochromatosis.

International journal of molecular sciences 20120101

Impaired iron status in aging research.

International journal of molecular sciences 20120101

Chelating agents for the treatment of systemic iron overload.

Current medicinal chemistry 20120101

Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.

Hemoglobin 20120101

Recent Advances in the Use of Drosophila melanogaster as a Model to Study Immunopathogenesis of Medically Important Filamentous Fungi.

International journal of microbiology 20120101

Progress towards mechanism-based treatment for Diamond-Blackfan anemia.

TheScientificWorldJournal 20120101

1B/(-)IRE DMT1 expression during brain ischemia contributes to cell death mediated by NF-κB/RelA acetylation at Lys310.

PloS one 20120101

Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.

Acta haematologica 20120101

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial.

Anemia 20120101

Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.

Cancer research 20111215

Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy.

Clinica chimica acta; international journal of clinical chemistry 20111120

Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.

Toxicology 20111118

Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function.

European journal of haematology 20111101

Challenges of adherence and persistence with iron chelation therapy.

International journal of hematology 20111101

Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia.

Pediatric hematology and oncology 20111101

Deferasirox induced liver injury in haemochromatosis.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 20111101

Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.

Blood cells, molecules & diseases 20111015

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.

European journal of haematology 20111001

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study.

European journal of haematology 20111001

Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia.

European journal of haematology 20111001

Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.

Gastroenterology 20111001

Chelation therapy for secondary iron overload: is the primary effect less iron or less liver fibrosis?

Gastroenterology 20111001

Past, present & future scenario of thalassaemic care & control in India.

The Indian journal of medical research 20111001

The dilemma of hyperoxia following positive pressure mechanical ventilation: role of iron and the benefit of iron chelation with deferasirox.

European review for medical and pharmacological sciences 20111001

How I treat thalassemia.

Blood 20110929

The impact of two different doses of chelating therapy (deferasirox) on echocardiographic tissue Doppler indices in patients with thalassemia major.

European journal of haematology 20110901

Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.

British journal of haematology 20110901

Chelation treatment in sickle-cell-anaemia: much ado about nothing?

British journal of haematology 20110901

Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.

Leukemia research 20110901

[In vitro effect of iron overload on bone marrow cell function by inducing the reactive oxygen species].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110901

Rapid monitoring of iron-chelating therapy in thalassemia major by a new cardiovascular MR measure: the reduced transverse relaxation rate.

NMR in biomedicine 20110801

Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.

British journal of haematology 20110801

Iron homeostasis--Achilles' heel of Aspergillus fumigatus?

Current opinion in microbiology 20110801

Response to effect of deferasirox on iron absorption in a randomized, placebo-controlled, crossover study in a human model of acute supratherapeutic iron ingestion.

Annals of emergency medicine 20110801

Managing unresponsiveness or intolerance to deferasirox therapy: a tale of two doses.

Expert review of hematology 20110801

[Establishment of iron overloaded bone marrow model in vitro and its impact on hematopoiesis].

Zhongguo shi yan xue ye xue za zhi 20110801

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

Blood 20110728

Effect of deferasirox on iron absorption in a randomized, placebo-controlled, crossover study in a human model of acute supratherapeutic iron ingestion.

Annals of emergency medicine 20110701

Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.

Haematologica 20110701

Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Hepatology (Baltimore, Md.) 20110701

Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.

Internal medicine journal 20110701

Iron chelator deferasirox rescued mice from Fas-induced fulminant hepatitis.

Hepatology research : the official journal of the Japan Society of Hepatology 20110701

[Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 20110701

Health-related quality of life in Thai thalassemic children treated with iron chelation.

The Southeast Asian journal of tropical medicine and public health 20110701

Recent advances in β-thalassemias.

Pediatric reports 20110616

Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.

Blood cells, molecules & diseases 20110615

Effects of deferasirox on renal function and renal epithelial cell death.

Toxicology letters 20110610

Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20110601

Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.

Annals of hematology 20110601

A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS.

Annals of hematology 20110601

Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.

American journal of physiology. Gastrointestinal and liver physiology 20110601

Pharmacoeconomic considerations in treating iron overload in patients with β-thalassaemia, sickle cell disease and myelodysplastic syndromes in the US: a literature review.

PharmacoEconomics 20110601

Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.

Translational research : the journal of laboratory and clinical medicine 20110601

Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.

Transfusion 20110501

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.

Leukemia research 20110501

Chelation of cadmium by combining deferasirox and deferiprone in rats.

Toxicology and industrial health 20110501

In vitro antimalarial activity of ICL670: a further proof of the correlation between inhibition of β-hematin formation and of peroxidative degradation of hemin.

Experimental parasitology 20110501

Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia?

Angiology 20110501

Comparison of changes in gene expression of transferrin receptor-1 and other iron-regulatory proteins in rat liver and brain during acute-phase response.

Cell and tissue research 20110501

Iron chelation adherence to deferoxamine and deferasirox in thalassemia.

American journal of hematology 20110501

Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia.

Anticancer research 20110501

The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.

Pediatric hematology and oncology 20110401

Reversible Fanconi syndrome in a pediatric patient on deferasirox.

Pediatric blood & cancer 20110401

Renal dysfunction in patients with thalassaemia.

British journal of haematology 20110401

Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.

British journal of haematology 20110401

Removal of thallium by deferasirox in rats as biological model.

Journal of applied toxicology : JAT 20110301

Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.

Pediatric blood & cancer 20110301

Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®).

European journal of haematology 20110301

Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox.

International journal of hematology 20110301

Absence of teratogenicity of deferasirox treatment during pregnancy in a thalassaemic patient.

Pediatric endocrinology reviews : PER 20110301

Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.

Journal of neural transmission (Vienna, Austria : 1996) 20110201

Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.

Haematologica 20110201

Iron chelation in thalassemia: time to reconsider our comfort zones.

Expert review of hematology 20110201

Iron overload and allogeneic hematopoietic stem-cell transplantation.

Expert review of hematology 20110201

Iron-chelating therapy for transfusional iron overload.

The New England journal of medicine 20110113

Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.

Annals of hematology 20110101

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.

Haematologica 20110101

Iron-induced cardiac damage: role of apoptosis and deferasirox intervention.

The Journal of pharmacology and experimental therapeutics 20110101

Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9.

Molecular pharmacology 20110101

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.

Haematologica 20110101

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Journal of the National Comprehensive Cancer Network : JNCCN 20110101

Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids.

Medicinal chemistry (Shariqah (United Arab Emirates)) 20110101

Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.

Annals of tropical paediatrics 20110101

Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.

Acta haematologica 20110101

A case of well-tolerated and safe deferasirox administration during the first trimester of a spontaneous pregnancy in an advanced maternal age thalassemic patient.

Acta haematologica 20110101

Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients.

BMC medical ethics 20110101

Value of black blood T2* cardiovascular magnetic resonance.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

Gated myocardial perfusion scintigraphy in children with sickle cell anemia: correlation with echocardiography.

Revista espanola de medicina nuclear 20110101

Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

Deferasirox lacks in vitro activity against Fusarium and Scedosporium species and black molds.

Virulence 20110101

Rhizomucor and scedosporium infection post hematopoietic stem-cell transplant.

Case reports in medicine 20110101

The proceedings of the 19Th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload.

Hemoglobin 20110101

Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.

Hemoglobin 20110101

A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients.

Hemoglobin 20110101

Epidemiology of invasive fungal infections in the mediterranean area.

Mediterranean journal of hematology and infectious diseases 20110101

Zygomycosis in Immunocompromised non-Haematological Patients.

Mediterranean journal of hematology and infectious diseases 20110101

Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.

Clinical drug investigation 20110101

Myelodysplastic syndrome and histone deacetylase inhibitors: 'to be or not to be acetylated'?

Journal of biomedicine & biotechnology 20110101

Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia.

Acta haematologica 20110101

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients.

Anemia 20110101

Epidemiology and treatment approaches in management of invasive fungal infections.

Clinical epidemiology 20110101

To 'umbrella' the gonads in transfusion rain.

Journal of human reproductive sciences 20110101

Terbium-sensitized fluorescence method for the determination of deferasirox in biological fluids and tablet formulation.

Luminescence : the journal of biological and chemical luminescence 20110101

Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan.

BMC research notes 20110101

Iron chelation therapy for transfusional iron overload: a swift evolution.

Hemoglobin 20110101

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20110101

The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.

Acta haematologica 20110101

The role of galenic innovation in improving treatment compliance and persistence: three case studies.

ClinicoEconomics and outcomes research : CEOR 20110101

Real-world use of iron chelators.

Hematology. American Society of Hematology. Education Program 20110101

Synthesis and biological evaluation of bidentate 3-hydroxypyridin-4-ones iron chelating agents.

Research in pharmaceutical sciences 20110101

Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.

Journal of blood medicine 20110101

Recombinant human erythropoietin reduces plasminogen activator inhibitor and ameliorates pro-inflammatory responses following trauma.

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

Efficacy and safety of Iranian made Deferasirox (Osveral®) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study.

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101

Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.

Pediatric blood & cancer 20101215

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.

Leukemia research 20101201

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Leukemia research 20101201

Delineating parameters of iron overload in MDS patients treated with deferasirox.

Leukemia research 20101201

Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.

Journal of hepatology 20101201

Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.

British journal of haematology 20101201

Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.

Hematology/oncology clinics of North America 20101201

Deferasirox for managing iron overload in people with myelodysplastic syndrome.

The Cochrane database of systematic reviews 20101110

A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.

Hepatology (Baltimore, Md.) 20101101

Myelodysplastic syndromes--many new drugs, little therapeutic progress.

Mayo Clinic proceedings 20101101

Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.

Journal of pediatric hematology/oncology 20101101

Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Archives of toxicology 20101101

Recent advances in the treatment of mucormycosis.

Current infectious disease reports 20101101

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.

Blood 20101007

Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.

European journal of haematology 20101001

Antifungal therapy in invasive fungal infections.

Current opinion in pharmacology 20101001

Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire.

Journal of pediatric hematology/oncology 20101001

Iron chelation therapy for patients with sickle cell disease and iron overload.

American journal of hematology 20101001

Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.

Journal of pediatric hematology/oncology 20101001

Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.

American journal of hematology 20101001

Oral chelation: should it be used with young children?

Pediatric blood & cancer 20101001

[Deferasirox--a new oral iron chelator--review].

Zhongguo shi yan xue ye xue za zhi 20101001

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

Leukemia research 20100901

Deferasirox use after hematopoietic stem cell transplantation in pediatric patients with beta-thalassemia major: preliminary results.

Pediatric hematology and oncology 20100901

HapX-mediated adaption to iron starvation is crucial for virulence of Aspergillus fumigatus.

PLoS pathogens 20100901

Deferasirox for managing transfusional iron overload in people with sickle cell disease.

The Cochrane database of systematic reviews 20100804

A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.

Therapeutic drug monitoring 20100801

Clinical evaluation of Deferasirox for removal of cadmium ions in rat.

Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine 20100801

Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.

Haematologica 20100801

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Haematologica 20100801

Posttransplant oral iron-chelating therapy in patients with beta-thalassemia major.

Pediatric hematology and oncology 20100801

An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial.

Advances in therapy 20100801

Deferasirox induced liver injury in haemochromatosis.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 20100801

Pathogenesis and management of iron toxicity in thalassemia.

Annals of the New York Academy of Sciences 20100801

Combined iron chelation therapy.

Annals of the New York Academy of Sciences 20100801

Deferasirox--current knowledge and future challenges.

Annals of the New York Academy of Sciences 20100801

Ninth Cooley's Anemia Symposium: summary and perspective.

Annals of the New York Academy of Sciences 20100801

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.

Blood 20100729

Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients.

Transfusion 20100701

Acute renal failure and Fanconi syndrome due to deferasirox.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100701

Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.

Journal of pediatric hematology/oncology 20100701

Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.

Expert opinion on drug safety 20100701

Chelation in metal intoxication.

International journal of environmental research and public health 20100701

Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.

Chemical research in toxicology 20100621

A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100601

Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver.

Cardiovascular toxicology 20100601

Daily alternating deferasirox and deferiprone therapy for 'hard-to-chelate' beta-thalassemia major patients.

American journal of hematology 20100601

The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.

Hemoglobin 20100601

Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.

Hemoglobin 20100601

Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy.

Mycoses 20100501

Complications and treatment of patients with β-thalassemia in France: results of the National Registry.

Haematologica 20100501

Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.

Drug metabolism and disposition: the biological fate of chemicals 20100501

Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.

Annals of hematology 20100401

Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes.

Journal of enzyme inhibition and medicinal chemistry 20100401

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.

Haematologica 20100401

Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.

Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine 20100401

Gastric ulcer in a child treated with deferasirox.

Pharmacy world & science : PWS 20100401

In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20100401

Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.

International journal of hematology 20100401

Iron chelation therapy in myelodysplastic syndromes.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100401

Acute interstitial nephritis secondary to deferasirox causing acute renal injury needing short-term dialysis.

Nephrology (Carlton, Vic.) 20100401

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.

Blood 20100325

Cystatin C levels in patients with beta-thalassemia during deferasirox treatment.

Blood cells, molecules & diseases 20100315

[Deferasirox-induced delayed hypersensitivity syndrome].

Medicina clinica 20100313

Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study.

Evidence-based complementary and alternative medicine : eCAM 20100301

Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.

Expert opinion on drug safety 20100301

Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.

International journal of hematology 20100301

Ability of deferasirox to bind iron during measurement of iron.

Clinical chemistry and laboratory medicine 20100301

Charge states of deferasirox-ferric iron complexes.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20100301

Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.

Journal of medicinal chemistry 20100211

Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.

Annals of hematology 20100201

Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.

Journal of clinical pharmacology 20100201

The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis.

The Journal of antimicrobial chemotherapy 20100201

Deferasirox treatment may be associated with reversible renal Fanconi syndrome.

American journal of hematology 20100201

Deferasirox: oral, once daily iron chelator--an expert opinion.

Indian journal of pediatrics 20100201

Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1,3,5-triazine family.

Bioorganic & medicinal chemistry letters 20100115

Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.

British journal of haematology 20100101

Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.

Acta haematologica 20100101

Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.

The Annals of pharmacotherapy 20100101

Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

Methods in molecular biology (Clifton, N.J.) 20100101

Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.

Acta haematologica 20100101

Iron overload in myelodysplastic syndromes: diagnosis and management.

Cancer control : journal of the Moffitt Cancer Center 20100101

Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

BMC cancer 20100101

Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.

Acta haematologica 20100101

Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.

Clinical drug investigation 20100101

Review of Journal of Cardiovascular Magnetic Resonance 2009.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20100101

Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome.

Advances in hematology 20100101

Production of metabolites as bacterial responses to the marine environment.

Marine drugs 20100101

Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20100101

Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.

Acta haematologica 20100101

Iron overload in sickle cell disease.

Advances in hematology 20100101

Beta-thalassemia.

Orphanet journal of rare diseases 20100101

beta-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload.

Advances in hematology 20100101

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

BMC health services research 20100101

Iron chelation therapy with deferasirox results in improvement of liver enzyme level in patients with iron overload-associated liver dysfunction.

Case reports in medicine 20100101

Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.

Acta haematologica 20100101

A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.

BMC health services research 20100101

Iron chelation therapy in myelodysplastic syndromes.

Advances in hematology 20100101

[Epidemiological and economic aspects of chelating therapy in the therapeutic center of thalassemia in Morocco].

Revue medicale de Bruxelles 20100101

[Diamond-Blackfan anemia. Case report].

Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 20100101

Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.

Journal of medical economics 20100101

Iron overload in patients undergoing hematopoietic stem cell transplantation.

Advances in hematology 20100101

HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox.

Acta haematologica 20100101

Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.

Hematology/oncology and stem cell therapy 20100101

Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a.

BMC research notes 20100101

The pro-BNP Serum Level and Echocardiographic Tissue Doppler Abnormalities in Patients with Beta Thalassemia Major.

Clinical Medicine Insights. Cardiology 20100101

Update on iron chelators in thalassemia.

Hematology. American Society of Hematology. Education Program 20100101

New treatments for myelodysplastic syndromes.

Mediterranean journal of hematology and infectious diseases 20100101

Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy.

Annals of hematology 20091201

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.

British journal of haematology 20091201

Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients.

British journal of haematology 20091201

The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin.

Journal of biomolecular structure & dynamics 20091201

Early detection of iron overload in the heart: a key role for MRI!

The international journal of cardiovascular imaging 20091201

Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.

Blood reviews 20091201

Iron chelation therapy in MDS: what have we learnt recently?

Blood reviews 20091201

Optimizing iron chelation strategies in beta-thalassaemia major.

Blood reviews 20091201

Recent advances in improving the management of sickle cell disease.

Blood reviews 20091201

Synthetic and natural iron chelators: therapeutic potential and clinical use.

Future medicinal chemistry 20091201

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

Blood 20091105

Fanconi syndrome due to deferasirox.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20091101

Iron chelation therapy in the management of thalassemia: the Asian perspectives.

International journal of hematology 20091101

Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.

[Rinsho ketsueki] The Japanese journal of clinical hematology 20091101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20091101

Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration?

Annals of hematology 20091001

Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy.

Journal of pediatric hematology/oncology 20091001

The role of iron and iron chelators in zygomycosis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20091001

Skin diseases in patients with beta-thalassemia major.

International journal of dermatology 20091001

Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.

Clinical journal of oncology nursing 20091001

Myelodysplasia paranoia: iron as the new radon.

Leukemia research 20090901

Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.

American journal of respiratory cell and molecular biology 20090901

ZYGOMYCOSIS: current approaches to management of patients with haematological malignancies.

British journal of haematology 20090901

Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice.

Medicinal chemistry (Shariqah (United Arab Emirates)) 20090901

Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.

American journal of hematology 20090901

Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.

Emerging infectious diseases 20090901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090901

Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.

Transfusion 20090801

Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.

Expert review of pharmacoeconomics & outcomes research 20090801

Iron chelation therapy in myelodysplastic syndrome - Cui bono?

Leukemia 20090801

Adult-onset erythropoietic porphyria in the setting of MDS.

Archives of dermatology 20090801

Iron is essential for oligodendrocyte genesis following intraspinal macrophage activation.

Experimental neurology 20090701

Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication.

PLoS genetics 20090701

[Pathogenesis of transfusional iron overload and iron chelation therapy].

[Rinsho ketsueki] The Japanese journal of clinical hematology 20090701

The treatment of secondary hemochromatosis.

Deutsches Arzteblatt international 20090701

Recent advances in the management of mucormycosis: from bench to bedside.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090615

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.

European journal of haematology 20090601

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.

European journal of haematology 20090601

Oral iron chelation and the treatment of iron overload in a pediatric hematology center.

Pediatric blood & cancer 20090501

Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.

Experimental biology and medicine (Maywood, N.J.) 20090501

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.

Cancer science 20090501

Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.

European journal of clinical investigation 20090501

Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload.

International journal of hematology 20090501

Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.

The oncologist 20090501

Deferasirox does not induce QT/QTc-prolongation in healthy subjects.

International journal of clinical pharmacology and therapeutics 20090501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090501

Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.

Annals of hematology 20090401

Deferasirox in pyruvate kinase deficiency.

Annals of hematology 20090401

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090401

Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia.

Pediatric blood & cancer 20090301

Cost analysis of iron-related complications in a single institute.

The Korean journal of internal medicine 20090301

Management of transfusional iron overload in Latin America: current outlook and expert panel recommendations.

Hematology (Amsterdam, Netherlands) 20090201

Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.

Health technology assessment (Winchester, England) 20090101

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

BMC medical genomics 20090101

Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.

Acta haematologica 20090101

The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20090101

Oral iron chelators.

Annual review of medicine 20090101

Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.

Hemoglobin 20090101

A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.

Hemoglobin 20090101

Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.

Hemoglobin 20090101

Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.

Hemoglobin 20090101

Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.

Retrovirology 20090101

Update on the use of deferasirox in the management of iron overload.

Therapeutics and clinical risk management 20090101

Deferasirox (Exjade) for the treatment of iron overload.

Acta haematologica 20090101

Prevention of cardiomyopathy in transfusion-dependent homozygous thalassaemia today and the role of cardiac magnetic resonance imaging.

Advances in hematology 20090101

Managing myelodysplastic symptoms in elderly patients.

Clinical interventions in aging 20090101

Deferasirox: an update.

Hemoglobin 20090101

Update on survival in thalassemia major.

Hemoglobin 20090101

Yersiniabactin reduces the respiratory oxidative stress response of innate immune cells.

PloS one 20090101

[Severe thrombocytopenia and mild leucopenia associated with deferasirox therapy].

Therapie 20090101

A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101

Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management.

Mediterranean journal of hematology and infectious diseases 20090101

Hematopietic stem cell transplantation in thalassemia and related disorders.

Mediterranean journal of hematology and infectious diseases 20090101

Hematopoietic stem cell transplantation in thalassemia and sickle cell disease. Unicenter experience in a multi-ethnic population.

Mediterranean journal of hematology and infectious diseases 20090101

Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications.

Mediterranean journal of hematology and infectious diseases 20090101

Iron chelation therapy in thalassemia syndromes.

Mediterranean journal of hematology and infectious diseases 20090101

Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.

Drug metabolism and disposition: the biological fate of chemicals 20081201

Deferasirox plus ciprofloxacin combination therapy after rapid diagnosis of Vibrio vulnificus sepsis using real-time polymerase chain reaction.

The Journal of infection 20081201

Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.

Current opinion in infectious diseases 20081201

The role of iron in patients after bone marrow transplantation.

Blood reviews 20081201

Long-term efficacy and safety of deferasirox.

Blood reviews 20081201

Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.

Expert opinion on drug safety 20081101

Current status in iron chelation in hemoglobinopathies.

Current molecular medicine 20081101

Acute interstitial nephritis due to deferasirox: a case report.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081001

Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.

International journal of clinical pharmacology and therapeutics 20081001

The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.

Journal of the National Comprehensive Cancer Network : JNCCN 20081001

Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.

Pediatric endocrinology reviews : PER 20081001

Treatment of iron overload in thalassemia.

Pediatric endocrinology reviews : PER 20081001

Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20080901

Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference.

British journal of haematology 20080901

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.

Expert opinion on pharmacotherapy 20080901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20080901

Targeting the lysosome: fluorescent iron(III) chelators to selectively monitor endosomal/lysosomal labile iron pools.

Journal of medicinal chemistry 20080814

Absolute oral bioavailability and disposition of deferasirox in healthy human subjects.

Journal of clinical pharmacology 20080801

Acute kidney injury due to deferoxamine in a renal transplant patient.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080801

Current approach to hemochromatosis.

Blood reviews 20080701

Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart.

Magnetic resonance in medicine 20080701

A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.

International journal of hematology 20080701

Iron and hepatitis C: what can we learn from thalassemia major?

Liver international : official journal of the International Association for the Study of the Liver 20080701

Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.

Current medical research and opinion 20080601

Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.

Haematologica 20080601

Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10.

Haematologica 20080601

Clinical application of deferasirox: practical patient management.

American journal of hematology 20080501

Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major.

British journal of haematology 20080501

Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

Haematologica 20080501

What is new in iron overload?

European journal of pediatrics 20080401

Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.

Journal of neurology, neurosurgery, and psychiatry 20080401

Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.

Journal of clinical pharmacology 20080401

Oral iron chelators.

Pediatric clinics of North America 20080401

Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.

European journal of clinical investigation 20080301

Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver.

The American journal of pathology 20080301

Iron overload in myelodysplastic syndromes.

Leukemia & lymphoma 20080301

[Pathophysiology, diagnosis and treatment of anemia].

Nihon rinsho. Japanese journal of clinical medicine 20080301

[Iron overload and iron chelation therapy in transfusion-dependent patients].

Nihon rinsho. Japanese journal of clinical medicine 20080301

[Development trend in new therapeutic approaches for anemia].

Nihon rinsho. Japanese journal of clinical medicine 20080301

Electrocatalytic oxidation and determination of deferasirox and deferiprone on a nickel oxyhydroxide-modified electrode.

Analytical biochemistry 20080215

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.

European journal of haematology 20080201

The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management.

European journal of haematology 20080201

Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks.

International journal of clinical pharmacology and therapeutics 20080201

Strides made in red blood cell disorders, but substantial barriers to care remain.

JAMA 20080130

Transfusion-dependent thalassaemia: a new era.

The Medical journal of Australia 20080121

Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.

The Biochemical journal 20080115

Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major.

Blood 20080115

Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.

Haematologica 20080101

Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.

Hemoglobin 20080101

Iron and the liver: update 2008.

Journal of hepatology 20080101

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.

Acta haematologica 20080101

Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.

International journal of hematology 20080101

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.

International journal of hematology 20080101

Body iron metabolism and pathophysiology of iron overload.

International journal of hematology 20080101

Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea.

International journal of hematology 20080101

Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20080101

Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.

Acta haematologica 20080101

Gateways to clinical trials. July-August 2008.

Methods and findings in experimental and clinical pharmacology 20080101

Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.

Acta haematologica 20080101

Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].

Hemoglobin 20080101

Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.

Hemoglobin 20080101

Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.

Hematology. American Society of Hematology. Education Program 20080101

Iron loading and its clinical implications.

American journal of hematology 20071201

Concepts and goals in the management of transfusional iron overload.

American journal of hematology 20071201

Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.

Leukemia research 20071201

Iron chelators ICL670 and 311 inhibit HIV-1 transcription.

Virology 20071025

Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.

Cell proliferation 20071001

Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.

Transfusion 20071001

Deferasirox: for iron overload: only a third-line option.

Prescrire international 20071001

Deferasirox for transfusion-related iron overload: a clinical review.

Clinical therapeutics 20071001

Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.

Therapeutics and clinical risk management 20071001

The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

The Journal of clinical investigation 20070904

Coordination chemistry and biology of chelators for the treatment of iron overload disorders.

Dalton transactions (Cambridge, England : 2003) 20070814

Iron chelation, quo vadis?

Current opinion in chemical biology 20070801

Light and shadows in the iron chelation treatment of haematological diseases.

British journal of haematology 20070801

Current status of iron overload and chelation with deferasirox.

Indian journal of pediatrics 20070801

Deferasirox: the new oral iron chelator.

Indian pediatrics 20070801

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.

Therapeutics and clinical risk management 20070801

Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.

Experimental hematology 20070701

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).

European journal of haematology 20070601

Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.

Therapeutics and clinical risk management 20070601

Cognitive declines therapy by iron burden reduction.

Archives of internal medicine 20070528

Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities.

Expert opinion on drug safety 20070501

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.

Clinical therapeutics 20070501

Deferasirox.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070315

Chelation therapy for iron overload.

Current gastroenterology reports 20070301

A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.

Journal of drugs in dermatology : JDD 20070301

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

British journal of haematology 20070201

Risk-based management of myelodysplastic syndrome.

Oncology (Williston Park, N.Y.) 20070101

Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.

PharmacoEconomics 20070101

Recent developments in iron chelation therapy.

Klinische Padiatrie 20070101

Deferasirox : a review of its use in the management of transfusional chronic iron overload.

Drugs 20070101

Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20070101

[Post transfusionnal iron overload].

La Revue du praticien 20061215

Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.

Oncology (Williston Park, N.Y.) 20061201

Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.

Blood 20061101

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.

Translational research : the journal of laboratory and clinical medicine 20061101

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Haematologica 20061001

Deferasirox: An effective once-daily orally active iron chelator.

Drugs of today (Barcelona, Spain : 1998) 20061001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20061001

Does liver biopsy overestimate liver iron concentration?

Blood 20060901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20060901

Investigational agents for sickle cell disease.

Expert opinion on investigational drugs 20060801

New drugs 06, part II.

Nursing 20060801

The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.

European journal of pharmacology 20060717

Deferasirox versus deferoxamine.

Blood 20060715

The oral chelator deferasirox--a new perspective for patients with iron overload.

Haematologica 20060701

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Haematologica 20060701

In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human.

Drug metabolism and disposition: the biological fate of chemicals 20060601

Deferasirox--an oral agent for chronic iron overload.

The Annals of pharmacotherapy 20060601

Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.

Haematologica 20060601

Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes.

Journal of enzyme inhibition and medicinal chemistry 20060601

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

Blood 20060501

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

Blood 20060501

Deferasirox (Exjade): a new iron chelator.

The Medical letter on drugs and therapeutics 20060424

New chelation therapies and emerging chelating drugs for the treatment of iron overload.

Expert opinion on emerging drugs 20060301

Exjade (ICL 670): A new oral iron chelator.

The Journal of the Association of Physicians of India 20060301

Iron chelation therapy for myelodysplastic syndrome: if and when.

Mayo Clinic proceedings 20060201

Myelodysplastic syndromes: iron overload consequences and current chelating therapies.

Journal of the National Comprehensive Cancer Network : JNCCN 20060101

Oral drug for iron overload.

FDA consumer 20060101

New drugs: ramelteon, tipranavir, nepafenac, and deferasirox.

Journal of the American Pharmacists Association : JAPhA 20060101

Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.

Hemoglobin 20060101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20060101

The impact of iron overload and its treatment on quality of life: results from a literature review.

Health and quality of life outcomes 20060101

[Clinical findings and therapy of classical hereditary haemochromatosis (type 1)].

Deutsche medizinische Wochenschrift (1946) 20051216

Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.

Blood 20051101

New therapies for sickle cell disease.

Hematology/oncology clinics of North America 20051001

Effects of ICL670 (deferasirox) on cardiac iron concentrations.

Lancet (London, England) 20050901

Molecule of the month. Deferasirox.

Drug news & perspectives 20050901

Deferasirox (ICL670; Exjade(R)), a Novel Orally Available Iron Chelator for Correction of Transfusion-Associated Iron Overload.

Supportive cancer therapy 20050701

Iron-chelating therapy with the new oral agent ICL670 (Exjade).

Best practice & research. Clinical haematology 20050601

Monitoring and treatment of iron overload: state of the art and new approaches.

Seminars in hematology 20050401

Treating iron overload: the state of the art.

Seminars in hematology 20050401

Iron chelation therapy.

Current hematology reports 20050301

Deferasirox Novartis.

Current opinion in investigational drugs (London, England : 2000) 20050301

The Egyptian experience with oral iron chelators.

Hematology (Amsterdam, Netherlands) 20050101

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.

Current medicinal chemistry 20050101

Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.

Current medicinal chemistry 20050101

Objectives and mechanism of iron chelation therapy.

Annals of the New York Academy of Sciences 20050101

The design of orally active iron chelators.

Annals of the New York Academy of Sciences 20050101

Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.

Annals of the New York Academy of Sciences 20050101

Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.

Annals of the New York Academy of Sciences 20050101

Acceptance of the 2003 John Howland Award: a journey in clinical research.

Pediatric research 20040801

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040101

The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin.

Free radical biology & medicine 20031201

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20031101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20030901

Do we need more iron-chelating drugs?

Lancet (London, England) 20030809

Development of tridentate iron chelators: from desferrithiocin to ICL670.

Current medicinal chemistry 20030601

Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.

Journal of clinical pharmacology 20030601

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.

Lancet (London, England) 20030510

Gateways to clinical trials. March 2003.

Methods and findings in experimental and clinical pharmacology 20030301

Clinical research: a tale of two studies.

Transactions of the American Clinical and Climatological Association 20030101

ICL670A: preclinical profile.

Advances in experimental medicine and biology 20020101

Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum.

British journal of haematology 20011201

Plasma deproteinization by precipitation and filtration in the 96-well format.

Journal of pharmaceutical and biomedical analysis 20010701

Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection.

Journal of chromatography. B, Biomedical sciences and applications 20010505

Practice of solid-phase extraction and protein precipitation in the 96-well format combined with high-performance liquid chromatography-ultraviolet detection for the analysis of drugs in plasma and brain.

Journal of chromatography. B, Biomedical sciences and applications 20010415

ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.

Blood 20010215